Kaempferol is a flavonoid found in many fruits, vegetables, and herbs, and has attracted interest for its neuroprotective properties, including potential relevance to Parkinson’s Disease (PD). Several preclinical (cell culture and animal) studies suggest that kaempferol may exert beneficial effects in PD models through antioxidant, anti-inflammatory, and anti-apoptotic pathways. For example, kaempferol has been shown to mitigate dopaminergic neuronal degeneration induced by toxins such as MPTP and rotenone in rodents, likely via reducing oxidative stress and modulating neuroinflammation. Some studies also indicate kaempferol may inhibit alpha-synuclein aggregation, a key process implicated in PD pathology.

However, there is currently no direct clinical evidence in humans supporting the use of kaempferol for the treatment or prevention of Parkinson’s Disease. The available evidence is limited to laboratory and animal studies. While these findings are promising and justify further research, they are not sufficient for clinical recommendation. Kaempferol is not currently used as a standard or mainstream treatment for PD, and its safety and efficacy in human patients with Parkinson’s Disease remain unproven. Thus, while a scientific rationale exists based on mechanistic and preclinical data, robust clinical validation is lacking.